Antidepressants: gradual and accompanied withdrawal avoids relapse risk

Many patients hesitate to stop antidepressants due to fears of withdrawal syndrome or symptom relapse. A study published in The Lancet shows that a gradual withdrawal, combined with psychological support, does not increase relapse risk compared to continuing the treatment.

Stopping antidepressants often poses a major challenge for patients with depressive or anxiety disorders. Many extend their treatment for years, fearing the return of symptoms or the effects of poorly managed withdrawal. A recent study, conducted by French experts and published on December 11, 2025, in The Lancet, provides reassuring insights on this issue.

The research compares two approaches: continuing the treatment and a gradual withdrawal accompanied by psychological support. The findings show that both methods are equally safe, with similar relapse risks. They are far preferable to an abrupt interruption or rapid dose reduction, which heighten complications.

Florian Naudet, professor at the University of Rennes and lead author of the study, states: “These two strategies – cautious withdrawal and continuing the treatment – are both safer than an abrupt interruption and a rapid reduction of antidepressants. Patients who are considering it should know that it is possible to stop, provided it is done within a shared decision with their doctor and with proper support.”

This publication highlights the importance of a shared decision between patient and physician, along with tailored support. It may encourage more individuals to consider a controlled withdrawal, while avoiding the pitfalls of a hasty cessation. The researchers emphasize the need for personalized follow-up to minimize risks associated with long-term treatments.

Awọn iroyin ti o ni ibatan

A doctor giving an injection to a patient in a clinic with brain scans in the background, illustrating a trial on immune drug for depression.
Àwòrán tí AI ṣe

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.

Health and Human Services Secretary Robert F. Kennedy Jr. unveiled a federal initiative that he says is intended to curb what the department describes as inappropriate prescribing of psychiatric medications — including widely used antidepressants such as Prozac and Zoloft — while expanding access to nonmedication treatments like psychotherapy and family support services. Mental health groups and psychiatrists said some elements, including better training and safer tapering support, could be helpful, but criticized Kennedy’s framing as too simplistic.

Ti AI ṣe iroyin

Researchers at Cedars-Sinai analyzed nearly 20 years of health records from over 650,000 U.S. adults with irritable bowel syndrome, finding associations between certain medications and increased mortality. Antidepressants were linked to a 35% higher risk of death, while loperamide and diphenoxylate showed about double the risk compared to non-users. Other IBS treatments like FDA-approved drugs and antispasmodics showed no such increase.

A one-year course of the drug abatacept can delay the onset of rheumatoid arthritis by up to four years in high-risk individuals. The benefits persisted long after treatment stopped, according to new research from King's College London.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ